Skip to main content
. 2021 Feb 17;10:625911. doi: 10.3389/fonc.2020.625911

Figure 3.

Figure 3

Combination effect of IL-8 and ICAM-1 for PFS prediction. Group 1: IL-8 >4.34 pg/ml, ICAM-1 ≤412.23 ng/ml; Group 2: IL-8 >4.34 pg/ml, ICAM-1 >412.23 ng/ml or IL-8 ≤4.34 pg/ml, ICAM-1 ≤412.23 ng/ml; Group 3: IL-8 ≤4.34 pg/ml, ICAM-1 >412.23 ng/ml. PFS was defined as the time from the first day of radiotherapy to the date of any progression, death, and loss to follow-up. Patients were censored at the last follow-up if no progression or death occurred.